BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Akorn, Inc. investors (“Akorn” or the “Company”) (NASDAQ: AKRX) concerning the Company and its officers’ possible violations of federal securities laws.
On January 9, 2019, Akorn announced that it had received a warning letter "dated January 4, from the U.S. Food and Drug Administration (FDA) related to an inspection of its Decatur, Illinois manufacturing facility in April and May of 2018." The warning letter from the FDA detailed a laundry list of "significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals". On this news, shares of Akorn fell $0.46 per share or over 11.6% to close at $3.48 per share on January 9, 2019, thereby damaging investors.
If you purchased Akorn securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.